Nykode Therapeutics AS (OSL:NYKD)

Market Cap	1.02B +17.3%
Revenue (ttm)	73.37M +68.1%
Net Income	-109.89M
EPS	-0.38
Shares Out	326.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (31.51%)
Ex-Dividend Date	n/a

Volume	88,620
Average Volume	738,987
Open	3.200
Previous Close	3.120
Day's Range	3.054 - 3.238
52-Week Range	1.440 - 3.450
Beta	1.10
RSI	66.40
Earnings Date	Feb 25, 2026

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 62
• Stock Exchange: Oslo Børs
• Ticker Symbol: NYKD

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD